Selected article for: "low molecular weight heparin and lung injury"
Author: Savla, Shreya R.; Prabhavalkar, Kedar S.; Bhatt, Lokesh K.
Title: Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management
  • Cord-id: 52jw4ial
  • Document date: 2021_4_19
    • ID: 52jw4ial
    Snippet: INTRODUCTION: SARS-CoV-2, the causative agent of COVID-19, attacks the immune system causing an exaggerated and uncontrolled release of pro-inflammatory mediators (cytokine storm). Recent studies propose an active role of coagulation disorders in disease progression. This hypercoagulability has been displayed by marked increase in D-dimer in hospitalized patients. AREAS COVERED: This review summarizes the pathogenesis of SARS-CoV-2 infection, generation of cytokine storm, the interdependence bet
    Document: INTRODUCTION: SARS-CoV-2, the causative agent of COVID-19, attacks the immune system causing an exaggerated and uncontrolled release of pro-inflammatory mediators (cytokine storm). Recent studies propose an active role of coagulation disorders in disease progression. This hypercoagulability has been displayed by marked increase in D-dimer in hospitalized patients. AREAS COVERED: This review summarizes the pathogenesis of SARS-CoV-2 infection, generation of cytokine storm, the interdependence between inflammation and coagulation, its consequences and the possible management options for coagulation complications like venous thromboembolism (VTE), microthrombosis, disseminated intravascular coagulation (DIC), and systemic and local coagulopathy. We searched PubMed, Scopus, and Google Scholar for relevant reports using COVID-19, cytokine storm, and coagulation as keywords. EXPERT OPINION: A prophylactic dose of 5000–7500 units of low molecular weight heparin (LMWH) has been recommended for hospitalized COVID-19 patients in order to prevent VTE. Treatment dose of LMWH, based on disease severity, is being contemplated for patients showing a marked rise in levels of D-dimer due to possible pulmonary thrombi. Additionally, targeting PAR-1, thrombin, coagulation factor Xa and the complement system may be potentially useful in reducing SARS-CoV-2 infection induced lung injury, microvascular thrombosis, VTE and related outcomes like DIC and multi-organ failure.

    Search related documents:
    Co phrase search for related documents
    • absence presence and absolute contraindication: 1
    • absence presence and accepted fact: 1
    • absence presence and activate platelet: 1
    • absence presence and activation complement activation: 1
    • absence presence and activity role: 1, 2, 3, 4, 5, 6
    • absence presence and acute ards: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • absence presence and acute ards lung injury: 1
    • absence presence and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • absence presence and acute condition: 1
    • absence presence and acute lung injury: 1, 2, 3
    • absence presence and acute phase protein: 1
    • absolute contraindication and acute ards: 1
    • absolute contraindication and acute ards respiratory distress syndrome: 1
    • activation complement activation and acute ards: 1
    • activation complement activation and acute ards lung injury: 1
    • activation complement activation and acute ards respiratory distress syndrome: 1
    • activity role and acute ards lung injury: 1
    • activity role and acute ards respiratory distress syndrome: 1, 2, 3, 4
    • activity role and acute lung injury: 1, 2